Division of Gastroenterology and Hepatology, Virginia Mason Medical Center, Seattle, Washington.
Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Maryland.
Clin Gastroenterol Hepatol. 2017 May;15(5):738-745. doi: 10.1016/j.cgh.2016.12.021. Epub 2016 Dec 30.
BACKGROUND & AIMS: Acute cholecystitis in patients who are not candidates for surgery is often managed with percutaneous transhepatic gallbladder drainage (PT-GBD). Endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) with a lumen-apposing metal stent (LAMS) is an effective alternative to PT-GBD. We compared the technical success of EUS-GBD versus PT-GBD, and patient outcomes, numbers of adverse events (AEs), length of hospital stay, pain scores, and repeat interventions.
We performed a retrospective study to compare EUS-GBD versus PT-GBD at 7 centers (5 in the United States, 1 in Europe, and 1 in Asia), from 2013 through 2015, in management of acute cholecystitis in patients who are not candidates for surgery. A total of 90 patients (56 men) with acute cholecystitis (61 calculous, 29 acalculous) underwent EUS-GBD (n = 45) or PT-GBD (n = 45). Data were collected on technical success, clinical success (resolution of symptoms or laboratory and/or radiologic abnormalities within 3 days of intervention), and need for repeat intervention. Characteristics were compared using Student t tests for continuous variables and the chi-square test, or the Fisher exact test, when appropriate, for categorical variables. Adverse events were graded according to American Society for Gastrointestinal Endoscopy definitions and compared using the Fisher exact test. Postprocedure pain scores were compared using the Mann-Whitney U test.
Baseline characteristics, type, and clinical severity of cholecystitis were comparable between groups. In the EUS-GBD group, noncautery LAMS were used in 30 patients and cautery-enhanced LAMS were used in 15. Technical success was achieved for 98% of patients in the EUS-GBD and 100% of the patients in the PT-GBD group (P = .88). Clinical success was achieved by 96% of patients in the EUS-GBD group and 91% in the PT-GBD group (P = .20). There was a nonsignificant trend toward fewer AEs in the EUS-GBD group (5 patients; 11%) than in the PT-GBD group (14 patients; 32%) (P = .065). There were no significant differences in the severity of the AEs: mild, 2 in the EUS-GBD group versus 5 in the PT-GBD group (P = .27); moderate, 4 versus 3 (P = .98); severe, 1 versus 3 (P = .62); or deaths, 1 versus 3 (P = .61). The mean postprocedure pain score was lower in the EUS-GBD group than in the PT-GBD group (2.5 vs 6.5; P < .05). The EUS-GBD group had a shorter average length of stay in the hospital (3 days) than the PT-GBD group (9 days) (P < .05) and fewer repeat interventions (11 vs 112) (P < .05). The average number of repeat interventions per patients was 0.2 ± 0.4 EUS-GBD group versus 2.5 ± 2.8 in the PT-GBD group (P < .05). Median follow-up after drainage was comparable in EUS-GBD group (215 days; range, 1-621 days) versus the PT-GBD group (265 days; range, 1-1638 days).
EUS-GBD has similar technical and clinical success compared with PT-GBD and should be considered an alternative for patients who are not candidates for surgery. Patients who undergo EUS-GBD seem to have shorter hospital stays, lower pain scores, and fewer repeated interventions, with a trend toward fewer AEs. A prospective, comparative study is needed to confirm these results.
对于不适合手术的急性胆囊炎患者,通常采用经皮经肝胆囊引流术(PT-GBD)进行治疗。内镜超声引导下胆囊引流术(EUS-GBD)联合使用腔镜贴合金属支架(LAMS)是 PT-GBD 的有效替代方法。本研究比较了 EUS-GBD 与 PT-GBD 的技术成功率、患者结局、不良事件(AE)数量、住院时间、疼痛评分和重复干预情况。
我们进行了一项回顾性研究,比较了 2013 年至 2015 年期间在美国 5 家中心、欧洲 1 家中心和亚洲 1 家中心的 7 家中心中,EUS-GBD 与 PT-GBD 治疗不适合手术的急性胆囊炎患者的效果。共有 90 名(56 名男性)患有急性胆囊炎(61 名结石性,29 名非结石性)的患者接受了 EUS-GBD(n=45)或 PT-GBD(n=45)治疗。收集技术成功率、临床成功率(干预后 3 天内症状或实验室和/或影像学异常的缓解情况)和重复干预的需求等数据。使用学生 t 检验比较连续变量,使用卡方检验或 Fisher 确切检验(适当时)比较分类变量。根据美国胃肠内镜学会的定义对不良事件进行分级,并使用 Fisher 确切检验进行比较。使用 Mann-Whitney U 检验比较术后疼痛评分。
两组患者的基线特征、胆囊炎类型和临床严重程度相似。在 EUS-GBD 组中,30 名患者使用了非电切 LAMS,15 名患者使用了电切增强 LAMS。EUS-GBD 组的技术成功率为 98%,PT-GBD 组的技术成功率为 100%(P=0.88)。EUS-GBD 组的临床成功率为 96%,PT-GBD 组的临床成功率为 91%(P=0.20)。EUS-GBD 组的不良事件发生率(5 例;11%)低于 PT-GBD 组(14 例;32%),但差异无统计学意义(P=0.065)。两组不良事件的严重程度差异无统计学意义:轻度,EUS-GBD 组 2 例,PT-GBD 组 5 例(P=0.27);中度,EUS-GBD 组 4 例,PT-GBD 组 3 例(P=0.98);重度,EUS-GBD 组 1 例,PT-GBD 组 3 例(P=0.62);死亡,EUS-GBD 组 1 例,PT-GBD 组 3 例(P=0.61)。EUS-GBD 组的术后疼痛评分明显低于 PT-GBD 组(2.5 分比 6.5 分;P<0.05)。EUS-GBD 组的平均住院时间短于 PT-GBD 组(3 天比 9 天;P<0.05),重复干预次数少于 PT-GBD 组(11 次比 112 次;P<0.05)。EUS-GBD 组患者的平均重复干预次数为 0.2±0.4 次,PT-GBD 组为 2.5±2.8 次(P<0.05)。EUS-GBD 组和 PT-GBD 组的中位引流后随访时间相似(EUS-GBD 组 215 天,范围 1-621 天;PT-GBD 组 265 天,范围 1-1638 天)。
EUS-GBD 与 PT-GBD 相比具有相似的技术和临床成功率,对于不适合手术的患者应考虑作为替代治疗方法。接受 EUS-GBD 的患者住院时间较短,疼痛评分较低,重复干预次数较少,且不良事件发生率较低。需要前瞻性、对照研究来证实这些结果。